{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:11:44Z","timestamp":1792951904661,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["ZLRK202304"],"award-info":[{"award-number":["ZLRK202304"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["CFH-2024-1-2053"],"award-info":[{"award-number":["CFH-2024-1-2053"]}]},{"name":"supported by Beijing Municipal Science & Technology Commission","award":["No.Z221100007422045"],"award-info":[{"award-number":["No.Z221100007422045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04231-8","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:54:19Z","timestamp":1770616459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differentiation grade and combined positive score correlation in head and neck squamous cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Lifei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jugao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"3","key":"4231_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4231_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.mayocp.2015.12.017","volume":"91","author":"S Marur","year":"2016","unstructured":"Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386\u201396. https:\/\/doi.org\/10.1016\/j.mayocp.2015.12.017.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"4231_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3322\/caac.21389","volume":"67","author":"WM Lydiatt","year":"2017","unstructured":"Lydiatt WM, Patel SG, O\u2019Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122\u201337. https:\/\/doi.org\/10.3322\/caac.21389.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4231_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99\u2013115. https:\/\/doi.org\/10.1038\/s41573-018-0004-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"4231_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188940","volume":"1878","author":"M Raudenska","year":"2023","unstructured":"Raudenska M, Balvan J, Hanelova K, Bugajova M, Masarik M. Cancer-associated fibroblasts: mediators of head and neck tumor microenvironment remodeling. Biochimi Biophys Acta Rev Cancer. 2023;1878(5):188940. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188940.","journal-title":"Biochimi Biophys Acta Rev Cancer"},{"issue":"6","key":"4231_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017;24(6):311\u201335. https:\/\/doi.org\/10.1097\/PAP.0000000000000161.","journal-title":"Adv Anat Pathol"},{"key":"4231_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oraloncology.2017.05.002","volume":"70","author":"A De Meulenaere","year":"2017","unstructured":"De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J, Ferdinande L, et al. Turning the tide: clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncol. 2017;70:34\u201342. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.05.002.","journal-title":"Oral Oncol"},{"key":"4231_CR8","doi-asserted-by":"publisher","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915-1928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7. Epub 2019 Nov 1. Erratum in: Lancet. 2020 Jan 25;395(10220):272. https:\/\/doi.org\/10.1016\/S0140-6736(20)30116-1. Erratum in: Lancet. 2020 Feb 22;395(10224):564. https:\/\/doi.org\/10.1016\/S0140-6736(20)30254-3. Erratum in: Lancet. 2021 Jun 12;397(10291):2252. https:\/\/doi.org\/10.1016\/S0140-6736(21)01119-3. PMID: 31679945","DOI":"10.1016\/S0140-6736(19)32591-7"},{"issue":"5","key":"4231_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4231_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4231_CR11","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1200\/JCO.19.01213","volume":"38","author":"J Vuky","year":"2020","unstructured":"Vuky J, Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Bellmunt J, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020;38(23):2658\u201366. https:\/\/doi.org\/10.1200\/JCO.19.01213. Epub 2020 Jun 17 PMID: 32552471.","journal-title":"J Clin Oncol"},{"issue":"35","key":"4231_CR12","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138\u201348. https:\/\/doi.org\/10.1200\/JCO.20.01888.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4231_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334. https:\/\/doi.org\/10.1084\/jem.192.7.1027.","journal-title":"J Exp Med"},{"issue":"9","key":"4231_CR14","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391. https:\/\/doi.org\/10.1172\/JCI80011.","journal-title":"J Clin Invest"},{"issue":"4","key":"4231_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"4231_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158160","volume":"25","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhang Q, Zhang B, Dai Y, Gao Y, Li C, et al. Epstein-Barr viruses: their immune evasion strategies and implications for autoimmune diseases. Int J Mol Sci. 2024;25(15):8160. https:\/\/doi.org\/10.3390\/ijms25158160.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4231_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02611-3","volume":"10","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang Q, Tao Y, Chen J, Yuan Z, Wang P. Characterization of immune microenvironment in patients with HPV-positive and negative head and neck cancer. Sci Data. 2023;10(1):694. https:\/\/doi.org\/10.1038\/s41597-023-02611-3.","journal-title":"Sci Data"},{"issue":"6","key":"4231_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011851","volume":"13","author":"N Zwing","year":"2025","unstructured":"Zwing N, von Voith Voithenberg L, Alberti L, et al. Mapping immune activity in HPV-negative head and neck squamous cell carcinoma: a spatial multiomics analysis. J Immunother Cancer. 2025;13(6):e011851. https:\/\/doi.org\/10.1136\/jitc-2025-011851.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4231_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.5306\/wjco.v13.i5.388","volume":"13","author":"JV Poulose","year":"2022","unstructured":"Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: a systematic review of phase-3 clinical trials. World J Clin Oncol. 2022;13(5):388\u2013411. https:\/\/doi.org\/10.5306\/wjco.v13.i5.388.","journal-title":"World J Clin Oncol"},{"key":"4231_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.placenta.2024.09.018","volume":"158","author":"SC Selvakumar","year":"2024","unstructured":"Selvakumar SC, Preethi KA, Ross K, Sekar D. The emerging role of microRNA-based therapeutics in the treatment of preeclampsia. Placenta. 2024;158:38\u201347. https:\/\/doi.org\/10.1016\/j.placenta.2024.09.018.","journal-title":"Placenta"},{"issue":"32","key":"4231_CR21","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.2174\/1381612823666170601100633","volume":"23","author":"T Isayeva","year":"2017","unstructured":"Isayeva T, Brandwein-Gensler M, Somarathna M, Moore-Smith LD, Lee T. Micro-RNA profiling as a predictor of clinical outcomes for head and neck cancer patients. Curr Pharm Des. 2017;23(32):4729\u201344. https:\/\/doi.org\/10.2174\/1381612823666170601100633.","journal-title":"Curr Pharm Des"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04231-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04231-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04231-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:01:36Z","timestamp":1773399696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04231-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4231"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04231-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (Approval No.:TREC2023-KY009). All participants provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}